GW Pharmaceuticals PLC- (GWPH) Given Average Rating of “Hold” by Brokerages

Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) have received a consensus recommendation of “Hold” from the eleven research firms that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $150.29.

GWPH has been the topic of several recent analyst reports. BidaskClub upgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. Goldman Sachs Group upgraded shares of GW Pharmaceuticals PLC- from a “neutral” rating to a “buy” rating and set a $174.00 price objective on the stock in a research note on Thursday, December 14th. Cantor Fitzgerald set a $208.00 price objective on shares of GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research note on Monday, December 4th. Bank of America lowered their price objective on shares of GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating on the stock in a research note on Tuesday, November 14th. Finally, Leerink Swann restated a “buy” rating and set a $153.00 price objective on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, January 23rd.

How to Become a New Pot Stock Millionaire

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada grew its stake in GW Pharmaceuticals PLC- by 0.4% in the 2nd quarter. Royal Bank of Canada now owns 4,240 shares of the biopharmaceutical company’s stock valued at $424,000 after buying an additional 18 shares during the last quarter. Ameriprise Financial Inc. grew its stake in GW Pharmaceuticals PLC- by 8.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 162 shares during the last quarter. Eqis Capital Management Inc. grew its stake in GW Pharmaceuticals PLC- by 12.6% in the 4th quarter. Eqis Capital Management Inc. now owns 3,791 shares of the biopharmaceutical company’s stock valued at $500,000 after buying an additional 424 shares during the last quarter. Aperio Group LLC grew its stake in GW Pharmaceuticals PLC- by 12.0% in the 4th quarter. Aperio Group LLC now owns 5,325 shares of the biopharmaceutical company’s stock valued at $703,000 after buying an additional 569 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. grew its stake in GW Pharmaceuticals PLC- by 18.6% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 3,700 shares of the biopharmaceutical company’s stock valued at $376,000 after buying an additional 581 shares during the last quarter. Institutional investors and hedge funds own 82.64% of the company’s stock.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) opened at $117.04 on Friday. The firm has a market cap of $3,210.00, a PE ratio of -13.22 and a beta of 2.63. GW Pharmaceuticals PLC- has a 52 week low of $92.65 and a 52 week high of $143.37. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.34 and a current ratio of 11.44.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing the consensus estimate of ($2.03) by ($0.40). The firm had revenue of $7.73 million for the quarter, compared to analyst estimates of $2.18 million. GW Pharmaceuticals PLC- had a negative return on equity of 46.94% and a negative net margin of 1,357.98%. research analysts predict that GW Pharmaceuticals PLC- will post -8.95 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first published by Enterprise Leader and is owned by of Enterprise Leader. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://theenterpriseleader.com/2018/04/02/gw-pharmaceuticals-plc-gwph-given-average-rating-of-hold-by-brokerages.html.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply